Salute e Benessere
IBA Business Update Q1 2025
- IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the first quarter of 2025.
Performance year-to-date progresses in line with expectations. We reiterate the guidance shared early April at the Capital Markets Day, as summarized below.
IBA is confident in its ability to deliver sustained profitability, whilst continuing to closely monitor the evolving macroeconomic conditions, particularly developments related to US tariffs. As stated at the Capital Markets Day, we maintain our expectation of a low to medium impact, with mitigation measures under assessment.
***ENDS***
Half Year Results 2025 28 August 2025
Business Update Q3 2025 20 November 2025
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.
IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com.
Unaudited
Proteus PLUS and Proteus ONE are brand names of Proteus®235
European Society for Radiotherapy and Oncology
Compact Automated Scalable SYnthesis
International Food Ionizing Processing Symposium
Attachment
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti